0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Commentary | Evidence-Based Dermatology

Risk of Malignant Disease and Biologic Response Modifiers Fact, Fiction, and Future Concerns

Vinod E. Nambudiri, MD, MBA1,2; Michael E. Bigby, MD1,3
[+] Author Affiliations
1Department of Dermatology, Harvard Medical School, Boston, Massachusetts
2Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
3Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
JAMA Dermatol. 2013;149(10):1221-1223. doi:10.1001/jamadermatol.2013.5738.
Text Size: A A A
Published online

Extract

Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-analysis

Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al.

JAMA. 2012;308(9):898-908.

Question: What is the risk of malignant disease in patients with rheumatoid arthritis (RA) treated with biologic response modifiers (BRMs)?

Data Sources: Cochrane Collaboration methods were followed. Randomized controlled trials (RCTs) examining the role of abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, and tocilizumab in rheumatoid arthritis were identified from comprehensive literatures searches of electronic databases, conference proceedings, and regulatory agency websites. All studies of human subjects published in English, French, or Spanish from inception through July 9, 2012, were identified.

Study Selection: Four pairs of independent reviewers identified randomized controlled trials that met the following inclusion criteria: (1) compared the safety of any BRM against placebo or any disease-modifying antirheumatic drug (DMARD); (2) included only patients with RA; and (3) reported a minimum of 24 weeks of follow-up.

Data Extraction: A total of 63 distinct trials with 29 423 patients met inclusion criteria, including 5991 patients from 20 studies of BRM monotherapy. Two independent reviewers extracted general information and characteristics of the study, population, and intervention from each selected trial. Two additional reviewers cross-checked the data. Primary outcome data of interest included overall number and type of malignant diseases developed by study participants. Authors of trials that did not report on number of malignant diseases were contacted for the specific data. Risk of bias of included studies was also appraised by the reviewers with each study ascribed a low, unclear, or high risk of bias score.

Data Synthesis: Data from the included studies were pooled, and Peto odds ratios (ORs) and relative risks with associated 95% confidence intervals were calculated for each BRM as well as for the subset of BRMs comprising tumor necrosis factor (TNF) inhibitors. Continuity correction estimates of the Peto ORs were generated to account for trials with no malignant diseases reported in either the intervention or control group (zero-total-event trials). Subgroup analyses were conducted to assess the impact of BRM monotherapy vs combination therapy with traditional DMARDs, as well as the impact of follow-up length, on malignant diseases development. Results were analyzed both at a 2-sided α level of significance of .05 and with a Bonferroni correction to control for multiple dosing regimens of each BRM.

Results: A total of 211 patients out of the 29 423 analyzed developed a malignant disease during the course of the trials (0.72%; 95% CI, 0.63%-0.82%), including 118 solid tumors, 48 skin cancers, 14 lymphomas, 5 nonlymphoma hematologic malignant diseases, and 26 unspecified cancers. No significantly increased risk of malignant disease was seen with any BRM monotherapy. Statistically significant increases in the risk of malignant diseases were seen in individuals treated with TNF inhibitors in combination with methotrexate compared with controls at 52 weeks (Peto OR, 2.1; 95% CI, 1.1-3.9) but not at other time points. Statistically significant lower odds of malignant disease were noted in patients treated with anakinra plus methotrexate compared with methotrexate alone at 24 weeks (Peto OR, 0.11; 95% CI, 0.03-0.45). Patients treated with anakinra also had significantly lower odds of developing nonmelanoma skin cancer (Peto OR, 0.06; 95% CI, 0.00-0.94).

Authors’ Conclusions: The authors conclude that the available data seem to suggest that there is no cumulative risk for the development of malignant diseases in patients with RA treated with BRMs.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

558 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();